מכפיל מחיר להכנסות עתידי LivaNova Corp (LIVN)

LivaNova PLC dominates epilepsy neuromodulation, leveraging inelastic demand and stable cash flow. The business's forward P/S illustrates patient brand loyalty regarding implant maintenance, where the value 2.50 represents the current figure. Predictable cash from cardiac surgery and steady operational momentum make the company a reliable asset whose long-term trend smooths out market noise.

Forward P/S determines the market value of a company relative to expected sales, allowing an investor to assess the extent of overpayment for future cash flows. An analysis of the future P/S of LivaNova PLC reflects market expectations for growth in cardiology procedure volumes and the success of neuromodulation, confirming the company's fundamental stability amid the optimization of internal costs.